Oncotarget

Research Papers:

Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses

Pu Xia _ and Xiao-Yan Xu

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:45538-45546. https://doi.org/10.18632/oncotarget.9998

Metrics: PDF 2451 views  |   HTML 1748 views  |   ?  


Abstract

Pu Xia1, Xiao-Yan Xu2

1Department of Cell Biology, College of Basic Medical Science, Liaoning Medical University, Jinzhou, Liaoning, P.R. China

2Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning, P.R. China

Correspondence to:

Pu Xia, email: nn001007@163.com

Keywords: CD44, The Cancer Genome Atlas, gastric cancer, colon cancer, bioinformatic analyses

Received: May 06, 2016     Accepted: May 29, 2016     Published: June 14, 2016

ABSTRACT

CD44 is a well-recognized stem cell biomarker expressed in colon and gastric cancer. In order to identify whether CD44 mRNA could be used as a prognostic marker in colon and gastric cancer, bioinformatic analyses were used in this study. cBioPortal analysis and COSMIC analysis were used to explore the CD44 mutation. CD44 mRNA levels were evaluated by using SAGE Genie tools and Oncomine analysis. Kaplan-Meier Plotter was performed to identify the prognostic roles of CD44 mRNA in these two cancers. In this study, first, we found that low alteration frequency of CD44 mRNA in colon and gastric cancer. Second, the high CD44 mRNA level was found in colon and gastric cancer, and it correlated with a benign survival rate in gastric cancer. Third, CD4 and CD74 may be used as markers to predict the prognosis of colon and gastric cancer. However, the deep mechanism(s) of these results remains unclear, further studies have to be performed in the future.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9998